POwER

Conditions

HIV/AIDS

Bodley N, Govender K, Moodley P, Samsunder N, Sookrajh Y, Turner PJ, Butler CC, Hayward GN, Gandhi M, Drain PK, Garrett N, Dorward J.

2026-08-01

10.1097/qai.0000000000003866

Diagnostic accuracy of a point‐of‐care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz‐based antiretroviral therapy

Jienchi Dorward, Richard Lessells, Katya Govender, Pravi Moodley, Natasha Samsunder et al. (12 authors)

Journal of the International AIDS Society2023-09-0110 citations

10.1002/jia2.26172

Point-of-Care Viral Load Testing to Manage HIV Viremia During the Rollout of Dolutegravir-Based ART in South Africa: A Randomized Feasibility Study (POwER)

Jienchi Dorward, Yukteshwar Sookrajh, Richard Lessells, Elliot Bulo, Jessica Naidoo et al. (16 authors)

JAIDS Journal of Acquired Immune Deficiency Syndromes2023-04-2510 citations

10.1097/qai.0000000000003212

Protocol for a randomised feasibility study of Point-Of-care HIV viral load testing to Enhance Re-suppression in South Africa: the POwER study

Jienchi Dorward, Yukteshwar Sookrajh, Hope Ngobese, Richard Lessells, Fathima Sayed et al. (14 authors)

BMJ Open2021-02-0111 citations

10.1136/bmjopen-2020-045373

Interventions

Point of care HIV viral load testing

Standard of care laboratory viral load testing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participant is willing and able to give informed consent for participation in the study. HIV positive adult, Male or Female, aged =18 years. Receiving first-line ART Latest viral load in the past 10 weeks =1000 copies/mL

Exclusion criteria

Exclusion criteria: Has already received enhanced adherence counselling Requires hospital admission Pregnant

Design outcomes

Primary

Measure	Time frame
The proportion of participants in each arm with viral load <50 copies/mL measured on laboratory reference assay	—

Secondary

Measure	Time frame
Proportion of patients with viraemia at the study clinic who are successfully enrolled in the study ;Proportion of enrolled participants who attend the study exit visit;The proportion of point-of-care viral load tests that are communicated to participants on the same day ;The proportion of point-of-care viral load tests =1000 copies/mL that result in same day enhanced adherence counselling;The proportion of point-of-care viral load tests =1000 copies/mL that result in same day switch to second-line ART;To determine staff perspectives regarding implementation of point-of-care viral load testing in a routine clinic	—

Measure

Time frame

Proportion of patients with viraemia at the study clinic who are successfully enrolled in the study ;Proportion of enrolled participants who attend the study exit visit;The proportion of point-of-care viral load tests that are communicated to participants on the same day ;The proportion of point-of-care viral load tests =1000 copies/mL that result in same day enhanced adherence counselling;The proportion of point-of-care viral load tests =1000 copies/mL that result in same day switch to second-line ART;To determine staff perspectives regarding implementation of point-of-care viral load testing in a routine clinic

—

Countries

South Africa

Contacts

Public ContactJienchi Dorward

Clinical Research Fellow

jienchi.dorward@phc.ox.ac.uk00441865289300

Outcome results

None listed